Net Cash Provided by (Used in) Operating Activities in USD of NeuBase Therapeutics, Inc. from 2010 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
NeuBase Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Operating Activities history and change rate from 2010 to Q1 2023.
  • NeuBase Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending 31 Mar 2023 was $3,447,911, a 58% increase year-over-year.
  • NeuBase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $29,011,966, a 54% decline from 2021.
  • NeuBase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was $18,873,684, a 76% decline from 2020.
  • NeuBase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2020 was $10,710,071, a 276% decline from 2019.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Change (%)

NeuBase Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $3,447,911 +$4,744,502 +58% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $5,687,848 -$419,402 -8% 01 Oct 2022 31 Dec 2022 10-QT 05 Jun 2023 2022 Q1
Q1 2022 $8,192,413 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $5,268,446 -$1,487,585 -39% 01 Oct 2021 31 Dec 2021 10-QT 05 Jun 2023 2022 Q1
Q4 2020 $3,780,861 -$1,339,375 -55% 01 Oct 2020 31 Dec 2020 10-Q 11 Feb 2022 2022 Q1
Q4 2019 $2,441,486 -$2,426,553 -16250% 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2021 Q1
Q4 2018 $14,933 +$4,180,708 +100% 01 Oct 2018 31 Dec 2018 10-Q 26 Mar 2020 2020 Q1
Q3 2018 $455* 28 Aug 2018 30 Sep 2018 10-K 10 Jan 2020 2019 FY
Q4 2017 $4,195,641 +$1,734,820 +29% 01 Oct 2017 31 Dec 2017 10-Q 14 Feb 2019 2019 Q1
Q4 2016 $5,930,461 01 Oct 2016 31 Dec 2016 10-Q 14 Feb 2018 2018 Q1
Q4 2014 $2,738,405 -$1,445,783 -112% 01 Oct 2014 31 Dec 2014 10-Q 10 Feb 2015 2015 Q1
Q4 2013 $1,292,622 -$631,474 -96% 01 Oct 2013 31 Dec 2013 10-Q 10 Feb 2015 2015 Q1
Q4 2012 $661,148 -$436,976 -195% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2014 Q1
Q4 2011 $224,172 -$61,074 -37% 01 Oct 2011 31 Dec 2011 10-Q 19 Feb 2013 2013 Q1
Q4 2010 $163,098 01 Oct 2010 31 Dec 2010 10-Q/A 14 Feb 2012 2012 Q1

NeuBase Therapeutics, Inc. Annual Net Cash Provided by (Used in) Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $29,011,966 -$10,138,282 -54% 01 Oct 2021 30 Sep 2022 10-K 21 Dec 2022 2022 FY
2021 $18,873,684 -$8,163,613 -76% 01 Oct 2020 30 Sep 2021 10-K 21 Dec 2022 2022 FY
2020 $10,710,071 -$7,864,583 -276% 01 Oct 2019 30 Sep 2020 10-K 23 Dec 2021 2021 FY
2019 $2,845,488 +$6,646,935 +70% 01 Oct 2018 30 Sep 2019 10-K 23 Dec 2020 2020 FY
2018 $9,492,423 +$9,798,549 +51% 01 Oct 2017 30 Sep 2018 10-K 03 Jan 2019 2018 FY
2017 $19,290,972 -$3,305,083 -21% 01 Oct 2016 30 Sep 2017 10-K 03 Jan 2019 2018 FY
2016 $15,985,889 01 Oct 2015 30 Sep 2016 10-K 15 Dec 2017 2017 FY
2014 $5,360,132 -$2,670,445 -99% 01 Oct 2013 30 Sep 2014 10-K 22 Dec 2014 2014 FY
2013 $2,689,687 -$935,858 -53% 01 Oct 2012 30 Sep 2013 10-K 22 Dec 2014 2014 FY
2012 $1,753,829 -$749,302 -75% 01 Oct 2011 30 Sep 2012 10-K 22 Dec 2014 2014 FY
2011 $1,004,527 -$482,742 -93% 01 Oct 2010 30 Sep 2011 10-K 09 Jan 2013 2012 FY
2010 $521,785 01 Oct 2009 30 Sep 2010 10-K/A 18 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.